Valuation: Verastem, Inc.

Market Cap 527M 462M 428M 394M 743M 50.78B 752M 5.11B 2B 24.89B 1.98B 1.94B 85.92B P/E 2026 *
-3.79x
P/E 2027 * -5.35x
Enterprise Value 362M 318M 294M 271M 511M 34.89B 517M 3.51B 1.37B 17.1B 1.36B 1.33B 59.03B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 1.78x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+4.35%
1 week+7.72%
Current month+57.07%
1 month+45.63%
3 months-0.83%
6 months-5.66%
Current year-22.28%
1 week 5.5
Extreme 5.505
6.22
1 month 3.43
Extreme 3.43
6.22
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap.
6/22/26 Sell

Chief Financial Officer

-4,089 0.0066%
6/22/26 Sell

Chief Executive Officer

-20,871 0.0339%
5/21/26 Free

Chairman

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+7.72%+17.65%-39.39% 505M
+0.88%-0.13%+57.39%+54.58% 53.79B
+1.80%+5.16%+53.09%+86.95% 54.69B
+1.50%-1.35%+5.68%+415.28% 23.2B
+0.18%+2.13%-15.22%-14.97% 23.31B
+1.46%+1.62%+38.64%-4.62% 20.03B
+0.30%-0.40%+33.13%-33.46% 17.31B
0.00%-2.08%+165.40%+297.92% 14.99B
+1.49%+2.67%+35.46%+586.58% 15.36B
+1.06%+0.63%+26.80%+185.02% 13.96B
Average +1.30%-0.69%+41.80%+153.39% 23.71B
Weighted average by Cap. +1.09%-1.63%+44.37%+136.40%

Financials

2026 *2027 *
Net sales 102M 89.29M 82.73M 76.15M 144M 9.81B 145M 987M 386M 4.81B 382M 374M 16.6B 178M 156M 145M 133M 251M 17.18B 254M 1.73B 676M 8.42B 669M 655M 29.06B
Net income -166M -145M -134M -124M -233M -15.94B -236M -1.6B -628M -7.81B -621M -608M -26.98B -142M -125M -115M -106M -200M -13.68B -203M -1.38B -539M -6.71B -533M -522M -23.15B
Net Debt -165M -145M -134M -123M -233M -15.89B -235M -1.6B -626M -7.79B -619M -606M -26.89B -210M -184M -170M -157M -295M -20.19B -299M -2.03B -795M -9.89B -787M -770M -34.16B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-07-21 US$6.000 +4.35% 2,532,153
26-07-20 US$5.750 -4.64% 2,532,687
26-07-17 US$6.030 +4.51% 3,562,397
26-07-16 US$5.770 +0.70% 1,985,572
26-07-15 US$5.730 +2.87% 2,083,595
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.000USD
Average target price
15.00USD
Spread / Average Target
+150.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock